Passage Bio (PASG)
NASDAQ:PASG
Want to see PASG full AI Analyst Report?
PASG Stock Chart & Stats
$11.68
>-$0.01(-0.86%)
At close: 4:00 PM EST
$11.68
>-$0.01(-0.86%)
Day’s Range― - ―
52-Week Range$5.12 - $20.00
Previous CloseN/A
Volume182.24K
Average Volume (3M)41.18K
Market Cap
$38.14M
Enterprise Value$15.14M
Total Cash (Recent Filing)$46.30M
Total Debt (Recent Filing)$24.01M
Price to Earnings (P/E)―
Beta2.33
Next Earnings
May 19, 2026EPS Estimate
-2.84Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-4.09
Shares Outstanding3,207,810
10 Day Avg. Volume55,130
30 Day Avg. Volume41,182
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)2.00
Price to Sales (P/S)0.00
P/FCF Ratio-1.19
Enterprise Value/Market Cap0.40
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-40.16
Enterprise Value/Ebitda-0.37
Forecast
1Y Price Target
$26.50Price Target Upside126.88% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)-8.56
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Biomarker EvidenceSustained increases in progranulin in cerebrospinal fluid and stabilization of neurofilament light support the therapy's biological activity and strengthen the evidence that the treatment may have a meaningful effect on disease biology.
Delivery And Procedure AdvantageA gene therapy that can be administered without brain surgery in a short outpatient procedure offers a less invasive profile than prior approaches, which could broaden patient acceptance and simplify trial logistics.
Regulatory Pathway PotentialRegulatory acceptance of a single-arm pivotal study for this rare disease and agency support for expedited development could simplify the approval pathway and reduce the regulatory burden for demonstrating benefit.
Bears Say
Class-level Oncogenesis ConcernA tumor report in a separate adeno-associated virus program showing viral genome integration and proto-oncogene activation raises class-level oncogenesis concerns that could lead regulators to require larger randomized trials and extended development timelines.
Funding And Cash RunwayLimited available cash represents a funding overhang that may necessitate additional financing and increase execution risk for ongoing development plans.
Serious Adverse EventA reported pulmonary embolism after a second dose prompted protocol amendments and highlights an unresolved safety risk that could complicate further dosing and regulator assessments.
Passage Bio News
PASG FAQ
What was Passage Bio’s price range in the past 12 months?
Passage Bio lowest stock price was $5.12 and its highest was $20.00 in the past 12 months.
What is Passage Bio’s market cap?
Passage Bio’s market cap is $38.14M.
When is Passage Bio’s upcoming earnings report date?
Passage Bio’s upcoming earnings report date is May 19, 2026 which is in 31 days.
How were Passage Bio’s earnings last quarter?
Passage Bio released its earnings results on Mar 03, 2026. The company reported -$4.09 earnings per share for the quarter, missing the consensus estimate of -$2.568 by -$1.522.
Is Passage Bio overvalued?
According to Wall Street analysts Passage Bio’s price is currently Undervalued.
Does Passage Bio pay dividends?
Passage Bio does not currently pay dividends.
What is Passage Bio’s EPS estimate?
Passage Bio’s EPS estimate is -2.84.
How many shares outstanding does Passage Bio have?
Passage Bio has 3,207,810 shares outstanding.
What happened to Passage Bio’s price movement after its last earnings report?
Passage Bio reported an EPS of -$4.09 in its last earnings report, missing expectations of -$2.568. Following the earnings report the stock price went down -8.884%.
Which hedge fund is a major shareholder of Passage Bio?
Currently, no hedge funds are holding shares in PASG
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Passage Bio Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$26.50 (126.88% Upside)
$26.50 (126.88% Upside)
Crowd Wisdom
Positive
Last 7 Days ▲ 1.2%
Last 30 Days ▲ 0.7%
Last 30 Days ▲ 0.7%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-27.84%
12-Months-Change
Fundamentals
Return on Equity
-87.18%
Trailing 12-Months
Asset Growth
-33.64%
Trailing 12-Months
Company Description
Passage Bio
Passage Bio, Inc., a genetic medicines company, develops transformative therapies for central nervous system diseases. It develops PBGM01, which utilizes a proprietary, AAVhu68 capsid to deliver to the brain and peripheral tissues a functional GLB1 gene encoding lysosomal acid beta-galactosidase for infantile GM1; PBFT02, which utilizes an AAV1 capsid to deliver to the brain a functional granulin (GRN) and gene encoding progranulin (PGRN) for the treatment of FTD-GRN; and PBKR03, which utilizes a proprietary, AAVhu68 capsid to deliver to the brain and peripheral tissues a functional GALC gene encoding the hydrolytic enzyme galactosylceramidase for infantile Krabbe disease. The company also develops PBML04 for the treatment of metachromatic leukodystrophy; PBAL05 for the treatment of amyotrophic lateral sclerosis; and PBCM06 for the treatment of Charcot-Marie-Tooth Type 2A. Passage Bio, Inc. has a strategic research collaboration with the Trustees of the University of Pennsylvania's Gene Therapy Program; and collaboration agreement, and a development services and clinical supply agreement with Catalent Maryland, Inc. The company was incorporated in 2017 and is headquartered in Philadelphia, Pennsylvania.
PASG Stock 12 Month Forecast
Average Price Target
$26.50
▲(126.88% Upside)
Technical Analysis
Tempest Therapeutics
―
Chemomab Therapeutics
―
Annovis Bio
―
―
Cognition Therapeutics
―
Ownership Overview
Currently, No data available
---